2025-522368-34-00CompletedPhase 1
A study investigating the safety, tolerability, pharmacokinetics (absorption, distribution, metabolism and elimination) and effect of single and multiple doses of MTX46943, a new compound that may potentially be used in the treatment of Alzheimer’s disease and other neurological disorders
Source: EU CTIS (euclinicaltrials.eu) · Last updated 26 Feb 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 123 (actual)
- First submitted
- 14 Jul 2025
- Start date
- 5 Sept 2025
- Lead sponsor
- Muna Therapeutics ApS
- Diseases
- Alzheimer disease
- EU CT number
- 2025-522368-34-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 123
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.